• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEM
Click for more information
0.00% 0.5¢

MEMPHASYS LIMITED. - Announcements

Market Cap $13.00M  ! watchlist Created with Sketch. Add to my watchlist

Memphasys Limited is an Australia-based reproductive biotechnology company. The Company... Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MEM Extension of Director line of creditPRICE SENSITIVE03/07/17
MEM Change in substantial holding - AG03/07/17
MEM Change of Director's Interest Notice - AG03/07/17
MEM Change of Director's Interest Notice - AC03/07/17
MEM SpermSep device development updatePRICE SENSITIVE29/06/17
MEM Cleansing Statement09/06/17
MEM Appendix 3B30/05/17
MEM Cleansing Statement18/05/17
MEM Update on SpermSep Device DevelopmentPRICE SENSITIVE18/05/17
MEM Appendix 3B17/05/17
MEM Cleansing Statement03/05/17
MEM Appendix 3B03/05/17
MEM ASX LR10.1 waiver on Director loan01/05/17
MEM Cleansing Statement19/04/17
MEM Appendix 3B19/04/17
MEM Completes sale of Gels business and Crescendas Loan clarificPRICE SENSITIVE06/04/17
MEM Disclosure Document04/04/17
MEM Appendix 3B04/04/17
MEM Commence next phase of SpermSep Development and new fundingPRICE SENSITIVE04/04/17
MEM Loan from Crescendas Projects and PrIME legal dispute updatePRICE SENSITIVE02/03/17
MEM Appendix 4D and Half Year Financial AccountsPRICE SENSITIVE28/02/17
MEM Funding Update - loan and line of creditPRICE SENSITIVE23/02/17
MEM Update on Dispute Resolution ProcessPRICE SENSITIVE17/02/17
MEM Statutory Demand To Be Set AsidePRICE SENSITIVE15/02/17
MEM Outome of legal action on preference B share call option16/01/17
MEM Memphasys' Capital Raising ReviewPRICE SENSITIVE16/12/16
MEM Capital RaisingPRICE SENSITIVE12/12/16
MEM Change of Director's Interest Notice JP Pereira01/12/16
MEM Waiver of ASX Listing Rule 10.101/12/16
MEM Company Secretary Appointment/Resignation29/11/16
MEM Results of Annual General Meeting28/11/16
MEM Chairman's Address to Shareholders for AGM25/11/16
MEM Memphasys' Investor Presentation 24 November 201624/11/16
MEM STATEMENT OF CLAIM FROM TRANSOCEAN SECURITIESPRICE SENSITIVE21/11/16
MEM Appendix 3B15/11/16
MEM Clarification Announcement -Convertible Notes15/11/16
MEM UPDATE ON LITIGATION AGAINST PRIMEPRICE SENSITIVE11/11/16
MEM Change in substantial holding-MEM.AX 01/11/16
MEM Change of Director's Interest Notice-MEM.AX 01/11/16
MEM Notice of Annual General Meeting-MEM.AX 31/10/16
MEM NOTICE OF AGM AND UPDATE RE OPTIONS FOR JANUARY 2016 PLACEME-MEM.AX 28/10/16
MEM Change of Director's Interest Notice-MEM.AX 14/10/16
MEM Change in substantial holding-MEM.AX 14/10/16
MEM R&D Tax Refund-MEM.AX 13/10/16
MEM Final Director's Interest Notice-MEM.AX 11/10/16
MEM Change in substantial holding-MEM.AX 07/10/16
MEM Change of Director's Interest Notice-MEM.AX 07/10/16
MEM Company Secretary Appointment/Resignation-MEM.AX 30/09/16
MEM Director Resignation - Dr. Gilmour-MEM.AX 29/09/16
MEM 2016 Appendix 4G-MEM.AX 28/09/16
MEM 2016 Corporate Governance Statement-MEM.AX 28/09/16
MEM Annual Report to shareholders-MEM.AX 28/09/16
MEM Capital Raising and New Corporate Advisor-MEM.AX PRICE SENSITIVE20/09/16
MEM Trading Halt-MEM.AX PRICE SENSITIVE16/09/16
MEM Response to ASX Appendix 3X Query-MEM.AX 15/09/16
MEM Initial Director's Interest Notice - J. Pereira-MEM.AX 14/09/16
MEM Correction to previous ASX Release-MEM.AX 12/09/16
MEM Letter of Demand from PrIME and Manukan re A-Bio Debt Repaym-MEM.AX PRICE SENSITIVE12/09/16
MEM Appendix 4E & FY2016 Preliminary Final Report-MEM.AX PRICE SENSITIVE31/08/16
MEM Director appointment-MEM.AX 30/08/16
MEM Change of Company Name to Memphasys-NSP.AX 04/07/16
MEM Emeritus Professor David Solomon Award-NSP.AX 27/06/16
MEM Extended Date for A-Bio Debt Repayment-NSP.AX PRICE SENSITIVE02/06/16
MEM Response to ASX Appendix 3Z query-NSP.AX 23/05/16
MEM NuSep commences litigation against PrIME-NSP.AX 17/05/16
MEM PrIME Capital Raising-NSP.AX PRICE SENSITIVE16/05/16
MEM Final Director's Interest Notice-NSP.AX 11/05/16
MEM Reinstatement to Official Quotation-NSP.AX PRICE SENSITIVE02/05/16
MEM Continuing Negotiations on sale of B Class shares in PrIME-NSP.AX PRICE SENSITIVE02/05/16
MEM Suspension from Official Quotation-NSP.AX PRICE SENSITIVE26/04/16
MEM Trading Halt-NSP.AX PRICE SENSITIVE21/04/16
MEM Initial Director's Interest Notice Dr. R Gilmour-NSP.AX 19/04/16
MEM Board changes-NSP.AX 12/04/16
MEM Sale of Gels Business-NSP.AX 12/04/16
MEM Change in substantial holding - A. Goodall-NSP.AX 08/04/16
MEM Change of Director's Interest Notice - A. Goodall-NSP.AX 08/04/16
MEM Change of Director's Interest Notice - M. Gell-NSP.AX 08/04/16
MEM Change of Director's Interest Notice - A Coutts-NSP.AX 08/04/16
MEM Entitlement Offer - Issue of New Shares-NSP.AX 05/04/16
MEM Results of In-vitro Clinical Evaluation at Monash IVF-NSP.AX 04/04/16
MEM Professor John Aitken wins Global Award31/03/16
MEM Entitlement Offer issue of shares and Appendix 3B18/03/16
MEM Non-Renounceable Entitlement Issue ClosurePRICE SENSITIVE15/03/16
MEM Non-Renounceable Entitlement Issue - Dispatch Of Documents01/03/16
MEM Replacement ProspectusPRICE SENSITIVE26/02/16
MEM Appendix 4D and Half Year Report December 2015PRICE SENSITIVE26/02/16
MEM Update on Non-renounceable Entitlement Offer24/02/16
MEM Non-renounceable Entitlement Offer23/02/16
MEM University of Newcastle AgreementPRICE SENSITIVE22/02/16
MEM Non-renounceable Entitlement OfferPRICE SENSITIVE16/02/16
MEM Non-Renounceable IssuePRICE SENSITIVE16/02/16
MEM Entitlement Offer and Appendix 3BPRICE SENSITIVE15/02/16
MEM Unlisted options expiry01/02/16
MEM Cleansing Notice14/01/16
MEM Appendix 3B14/01/16
MEM Private placementPRICE SENSITIVE11/01/16
MEM Trading HaltPRICE SENSITIVE07/01/16
MEM ANDREW GOODALL RESIGNS FROM PRIME BOARD06/01/16
MEM Director Appointment/Resignation04/01/16
MEM Options Expiry09/12/15
MEM Extension of Director line of credit
03/07/17PRICE SENSITIVE
MEM Change in substantial holding - AG
03/07/17
MEM Change of Director's Interest Notice - AG
03/07/17
MEM Change of Director's Interest Notice - AC
03/07/17
MEM SpermSep device development update
29/06/17PRICE SENSITIVE
MEM Cleansing Statement
09/06/17
MEM Appendix 3B
30/05/17
MEM Cleansing Statement
18/05/17
MEM Update on SpermSep Device Development
18/05/17PRICE SENSITIVE
MEM Appendix 3B
17/05/17
MEM Cleansing Statement
03/05/17
MEM Appendix 3B
03/05/17
MEM ASX LR10.1 waiver on Director loan
01/05/17
MEM Cleansing Statement
19/04/17
MEM Appendix 3B
19/04/17
MEM Completes sale of Gels business and Crescendas Loan clarific
06/04/17PRICE SENSITIVE
MEM Disclosure Document
04/04/17
MEM Appendix 3B
04/04/17
MEM Commence next phase of SpermSep Development and new funding
04/04/17PRICE SENSITIVE
MEM Loan from Crescendas Projects and PrIME legal dispute update
02/03/17PRICE SENSITIVE
MEM Appendix 4D and Half Year Financial Accounts
28/02/17PRICE SENSITIVE
MEM Funding Update - loan and line of credit
23/02/17PRICE SENSITIVE
MEM Update on Dispute Resolution Process
17/02/17PRICE SENSITIVE
MEM Statutory Demand To Be Set Aside
15/02/17PRICE SENSITIVE
MEM Outome of legal action on preference B share call option
16/01/17
MEM Memphasys' Capital Raising Review
16/12/16PRICE SENSITIVE
MEM Capital Raising
12/12/16PRICE SENSITIVE
MEM Change of Director's Interest Notice JP Pereira
01/12/16
MEM Waiver of ASX Listing Rule 10.1
01/12/16
MEM Company Secretary Appointment/Resignation
29/11/16
MEM Results of Annual General Meeting
28/11/16
MEM Chairman's Address to Shareholders for AGM
25/11/16
MEM Memphasys' Investor Presentation 24 November 2016
24/11/16
MEM STATEMENT OF CLAIM FROM TRANSOCEAN SECURITIES
21/11/16PRICE SENSITIVE
MEM Appendix 3B
15/11/16
MEM Clarification Announcement -Convertible Notes
15/11/16
MEM UPDATE ON LITIGATION AGAINST PRIME
11/11/16PRICE SENSITIVE
MEM Change in substantial holding-MEM.AX
01/11/16
MEM Change of Director's Interest Notice-MEM.AX
01/11/16
MEM Notice of Annual General Meeting-MEM.AX
31/10/16
MEM NOTICE OF AGM AND UPDATE RE OPTIONS FOR JANUARY 2016 PLACEME-MEM.AX
28/10/16
MEM Change of Director's Interest Notice-MEM.AX
14/10/16
MEM Change in substantial holding-MEM.AX
14/10/16
MEM R&D Tax Refund-MEM.AX
13/10/16
MEM Final Director's Interest Notice-MEM.AX
11/10/16
MEM Change in substantial holding-MEM.AX
07/10/16
MEM Change of Director's Interest Notice-MEM.AX
07/10/16
MEM Company Secretary Appointment/Resignation-MEM.AX
30/09/16
MEM Director Resignation - Dr. Gilmour-MEM.AX
29/09/16
MEM 2016 Appendix 4G-MEM.AX
28/09/16
MEM 2016 Corporate Governance Statement-MEM.AX
28/09/16
MEM Annual Report to shareholders-MEM.AX
28/09/16
MEM Capital Raising and New Corporate Advisor-MEM.AX
20/09/16PRICE SENSITIVE
MEM Trading Halt-MEM.AX
16/09/16PRICE SENSITIVE
MEM Response to ASX Appendix 3X Query-MEM.AX
15/09/16
MEM Initial Director's Interest Notice - J. Pereira-MEM.AX
14/09/16
MEM Correction to previous ASX Release-MEM.AX
12/09/16
MEM Letter of Demand from PrIME and Manukan re A-Bio Debt Repaym-MEM.AX
12/09/16PRICE SENSITIVE
MEM Appendix 4E & FY2016 Preliminary Final Report-MEM.AX
31/08/16PRICE SENSITIVE
MEM Director appointment-MEM.AX
30/08/16
MEM Change of Company Name to Memphasys-NSP.AX
04/07/16
MEM Emeritus Professor David Solomon Award-NSP.AX
27/06/16
MEM Extended Date for A-Bio Debt Repayment-NSP.AX
02/06/16PRICE SENSITIVE
MEM Response to ASX Appendix 3Z query-NSP.AX
23/05/16
MEM NuSep commences litigation against PrIME-NSP.AX
17/05/16
MEM PrIME Capital Raising-NSP.AX
16/05/16PRICE SENSITIVE
MEM Final Director's Interest Notice-NSP.AX
11/05/16
MEM Reinstatement to Official Quotation-NSP.AX
02/05/16PRICE SENSITIVE
MEM Continuing Negotiations on sale of B Class shares in PrIME-NSP.AX
02/05/16PRICE SENSITIVE
MEM Suspension from Official Quotation-NSP.AX
26/04/16PRICE SENSITIVE
MEM Trading Halt-NSP.AX
21/04/16PRICE SENSITIVE
MEM Initial Director's Interest Notice Dr. R Gilmour-NSP.AX
19/04/16
MEM Board changes-NSP.AX
12/04/16
MEM Sale of Gels Business-NSP.AX
12/04/16
MEM Change in substantial holding - A. Goodall-NSP.AX
08/04/16
MEM Change of Director's Interest Notice - A. Goodall-NSP.AX
08/04/16
MEM Change of Director's Interest Notice - M. Gell-NSP.AX
08/04/16
MEM Change of Director's Interest Notice - A Coutts-NSP.AX
08/04/16
MEM Entitlement Offer - Issue of New Shares-NSP.AX
05/04/16
MEM Results of In-vitro Clinical Evaluation at Monash IVF-NSP.AX
04/04/16
MEM Professor John Aitken wins Global Award
31/03/16
MEM Entitlement Offer issue of shares and Appendix 3B
18/03/16
MEM Non-Renounceable Entitlement Issue Closure
15/03/16PRICE SENSITIVE
MEM Non-Renounceable Entitlement Issue - Dispatch Of Documents
01/03/16
MEM Replacement Prospectus
26/02/16PRICE SENSITIVE
MEM Appendix 4D and Half Year Report December 2015
26/02/16PRICE SENSITIVE
MEM Update on Non-renounceable Entitlement Offer
24/02/16
MEM Non-renounceable Entitlement Offer
23/02/16
MEM University of Newcastle Agreement
22/02/16PRICE SENSITIVE
MEM Non-renounceable Entitlement Offer
16/02/16PRICE SENSITIVE
MEM Non-Renounceable Issue
16/02/16PRICE SENSITIVE
MEM Entitlement Offer and Appendix 3B
15/02/16PRICE SENSITIVE
MEM Unlisted options expiry
01/02/16
MEM Cleansing Notice
14/01/16
MEM Appendix 3B
14/01/16
MEM Private placement
11/01/16PRICE SENSITIVE
MEM Trading Halt
07/01/16PRICE SENSITIVE
MEM ANDREW GOODALL RESIGNS FROM PRIME BOARD
06/01/16
MEM Director Appointment/Resignation
04/01/16
MEM Options Expiry
09/12/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $13.00M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $12.5K 2.5M

Buyers (Bids)

No. Vol. Price($)
4 4139600 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 11066843 9
View Market Depth
Last trade - 15.45pm 29/11/2024 (20 minute delay) ?
Last
0.5¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 200000
Last updated 14.07pm 29/11/2024 ?
MEM (ASX) Chart

Top Stories

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia New Zealand’s Reserve Bank has taken a bold step, slashing rates by 50 basis points to 4.25% @ its third cut in just four months. Meanwhile, the Reserve Bank of Australia holds firm at 4.35%, its highest rate in over a decade.This stark policy divergence highlights contrasting glo...
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.